Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Phase 2
2(40.0%)
5Total
Phase 1(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07402551Phase 2Recruiting

Phase II Study of RC1416 Injection in COPD

Role: lead

NCT07403487Phase 2Not Yet Recruiting

Phase II Trial of RC1416 Injection in Asthma

Role: lead

NCT06911866Phase 1Completed

A Phase Ib Study of RC1416 Injection

Role: lead

NCT06756451Phase 1Recruiting

This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.

Role: lead

NCT06067490Phase 1Completed

A Phase I Study of RC1416 Injection

Role: lead

All 5 trials loaded